Miyagi Chihiro, Kuroda Taiyo, Karimov Jamshid H, Fukamachi Kiyotaka
Department of Biomedical Engineering, Cleveland Clinic, Lerner Research Institute, Cleveland, OH, United States.
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, United States.
Front Cardiovasc Med. 2022 Aug 11;9:910957. doi: 10.3389/fcvm.2022.910957. eCollection 2022.
The importance of the left atrium (LA) has been emphasized in recent years as the features of heart failure (HF), especially with regard to variability in patient and pathology phenotypes, continue to be uncovered. Of note, among the population with HF with preserved ejection fraction (HFpEF), pressure or size of the LA have become a target for advanced monitoring and a therapeutic approach. In the case of diastolic dysfunction or pulmonary hypertension, which are often observed in patients with HFpEF, a conventional approach with clinical symptoms and physical signs of decompensation turned out to have a poor correlation with LA pressure. Therefore, to optimize HF treatment for these populations, several devices that are applied directly to the LA have been developed. First, two LA pressure (LAP) sensors (Heart POD and V-LAP Device) were developed and may enable patient self-management remotely with LAP-guided and physician-directed style. Second, there are device-based approaches that aim to decompress the LA directly. These include: (1) interatrial shunt devices; (2) left ventricular assist devices with LA cannulation; and (3) the left atrial assist device. While these novel device-based therapies are not yet commercially available, there is expected to be a rise in the proposition and adoption of a wider range of choices for monitoring or treating LA using device-based options, based on LA dimensional reduction and optimization of the clinically significant pressure relief. Further development and evaluation are necessary to establish a more favorable management strategy for HF.
近年来,随着心力衰竭(HF)的特征,尤其是在患者和病理表型变异性方面,不断被发现,左心房(LA)的重要性得到了强调。值得注意的是,在射血分数保留的心力衰竭(HFpEF)患者群体中,左心房压力或大小已成为高级监测和治疗方法的目标。在HFpEF患者中经常观察到的舒张功能障碍或肺动脉高压的情况下,基于失代偿临床症状和体征的传统方法与左心房压力的相关性较差。因此,为了优化这些人群的心力衰竭治疗,已经开发了几种直接应用于左心房的装置。首先,开发了两种左心房压力(LAP)传感器(Heart POD和V-LAP装置),它们可以通过LAP引导和医生指导的方式实现患者远程自我管理。其次,有一些基于装置的方法旨在直接减轻左心房压力。这些方法包括:(1)房间隔分流装置;(2)带有左心房插管的左心室辅助装置;以及(3)左心房辅助装置。虽然这些基于新型装置的疗法尚未商业化,但基于左心房尺寸减小和临床显著压力缓解的优化,预计将出现更多基于装置的监测或治疗左心房的选择方案,并得到更多应用。为了建立更有利的心力衰竭管理策略,还需要进一步的开发和评估。